183 related articles for article (PubMed ID: 36413495)
1. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
[TBL] [Abstract][Full Text] [Related]
2. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
3. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
4. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
6. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
7. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
[TBL] [Abstract][Full Text] [Related]
8. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
10. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
11. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
12. High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience.
Kabut T; Weinbergerová B; Folber F; Lengerová M; Mayer J
Bone Marrow Transplant; 2023 Nov; 58(11):1229-1236. PubMed ID: 37612466
[TBL] [Abstract][Full Text] [Related]
13. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.
Karantoni E; Zavras PD; Su Y; Fang J; Tamari R; Cho C; Perales MA; Stern A; Papanicolaou GA
Transplant Cell Ther; 2022 Jul; 28(7):403.e1-403.e7. PubMed ID: 35476955
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Marty FM; Ljungman PT; Chemaly RF; Wan H; Teal VL; Butterton JR; Yeh WW; Leavitt RY; Badshah CS
Am J Transplant; 2020 Jun; 20(6):1703-1711. PubMed ID: 31883426
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
[TBL] [Abstract][Full Text] [Related]
17. High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Lam S; Boan P; Polistena P; Cannell P; Cooney J; Wright M; Purtill D
Transpl Infect Dis; 2021 Aug; 23(4):e13633. PubMed ID: 33978289
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
[TBL] [Abstract][Full Text] [Related]
19. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
20. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
